Written Authority Required Drugs 012-63060000

Letter

Drugs

A-K

See also: L-Z

abatacept, adalimumab, aflibercept, ambrisentan, anifrolumab, armodafinil, asciminib, avatrombopag, azacitidine, baricitinib, benralizumab, bimekizumab, blinatumomab, bosentan monohydrate, brentuximab vedotin, brolucizumab, burosumab, certolizumab pegol, crizotinib, dasatinib, daunorubicin+cytarabine, decitabine+cedazuridine, dexamethasone implant, difelikefalin, dupilumab, eculizumab, elexacaftor+tezacaftor+ivacaftor, elotuzumab, eltrombopag, entrectinib, epoprostenol sodium, etanercept, etrasimod, faricimab, golimumab, guselkumab, iloprost trometamol, imatinib, infliximab, ivacaftor, ixekizumab

Drugs

Description

abatacept (Orencia®)

Index

Abatacept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, abatacept is subsidised for the treatment of rheumatoid arthritis.

adalimumab (Humira®/Amgevita®/ Hadlima®/Hyrimoz®/Idacio®/ Yuflyma®)

Index

Adalimumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, adalimumab is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adult
• paediatric
• fistulising Crohn's disease
• hidradenitis suppurativa
• juvenile idiopathic arthritis
• non-infectious uveitis
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adult
• ulcerative colitis:
• adult
• paediatric

aflibercept (Eylea®)

Index

Aflibercept is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, aflibercept is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion with macular oedema
• subfoveal choroidal neovascularisation due to:
• age related macular degeneration
• pathologic myopia
• other causes

ambrisentan (Volibris®)

Index

Ambrisentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, ambrisentan is subsidised for the treatment of pulmonary arterial hypertension.

anifrolumab (Saphnelo®)

Index

Anifrolumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, anifrolumab is subsidised for the treatment of systemic lupus erythematosus.

armodafinil (Nuvigil®)

Index

Armodafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, armodafinil is subsidised for the treatment of narcolepsy.

asciminib (Scemblix®)

Index

Asciminib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, asciminib is subsidised for the treatment of chronic myeloid leukaemia.

avatrombopag (Doptelet®)

Index

Avatrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, avatrombopag is subsidised for the treatment of idiopathic thrombocytopenic purpura.

azacitidine (Vidaza®/Azadine®/ Celazadine®)

Index

Azacitidine is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, azacitidine is subsidised for the treatment of:

• myelodysplastic syndrome
• chronic myelomonocytic leukaemia
• acute myeloid leukaemia

baricitinib (Olumiant®)

Index

Baricitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, baricitinib is subsidised for the treatment of rheumatoid arthritis.

benralizumab (Fasenra®)

Index

Benralizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, benralizumab is subsidised for the treatment of:

• severe asthma:
• adult
• adolescent

bimekizumab (Bimzelx®)

Index

Bimekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, bimekizumab is subsidised for the treatment of:

• non-radiographic axial spondyloarthritis
• ankylosing spondylitis
• psoriatic arthritis
• severe chronic plaque psoriasis:
• adult

blinatumomab (Blincyto®)

Index

Blinatumomab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, blinatumomab is subsidised for the treatment of acute lymphoblastic leukaemia.

bosentan monohydrate (Tracleer®)

Index

Bosentan monohydrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, bosentan monohydrate is subsidised for the treatment of pulmonary arterial hypertension.

brentuximab vedotin (Adcetris®)

Index

Brentuximab vedotin is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, brentuximab is subsidised for the treatment of:

• CD30 positive systemic anaplastic large cell lymphoma
• relapsed or refractory Hodgkin lymphoma
• cutaneous T-cell lymphoma
• peripheral T-cell lymphoma

brolucizumab (Beovu®)

Index

Brolucizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, brolucizumab is subsidised for the treatment of age related macular degeneration (AMD).

burosumab (Crysvita®)

Index

Burosumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, burosumab is subsidised for the treatment of X-linked hypophosphataemia (XLH).

certolizumab pegol (Cimzia®)

Index

Certolizumab pegol is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, certolizumab is subsidised for the treatment of:

• rheumatoid arthritis
• ankylosing spondylitis
• psoriatic arthritis
• non-radiographic axial spondyloarthritis

crizotinib (Xalkori®)

Index

Crizotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, crizotinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer.

dasatinib (Sprycel®)

Index

Dasatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, dasatinib is subsidised for the treatment of:

• acute lymphoblastic leukaemia
• chronic myeloid leukaemia

daunorubicin+cytarabine (Vyxeos®)

Index

Daunorubicin+cytarabine is listed under Section 100 – Efficient funding of chemotherapy arrangements and administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, daunorubicin+cytarabine is subsidised for the treatment of acute myeloid leukaemia.

decitabine+cedazuridine (Inqovi®)

Index

Decitabine+cedazuridine is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, decitabine+cedazuridine is subsidised for the treatment of:

• acute myeloid leukaemia
• chronic myelomonocytic leukaemia
• myelodysplastic syndrome

dexamethasone implant (Ozurdex®)

Index

Dexamethasone is a Section 85 listed pharmaceutical benefit.

Providing the patient meets the specific restriction criteria, dexamethasone implant is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion macular oedema

difelikefalin (Korsuva®)

Index

Difelikefalin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, difelikefalin is subsidised for the treatment of chronic kidney disease-associated pruritus.

dupilumab (Dupixent®)

Index

Dupilumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, dupilumab is subsidised for the treatment of severe asthma.

eculizumab (Soliris®)

Index

Eculizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, eculizumab is subsidised for the treatment of:

• atypical haemolytic uraemic syndrome
• paroxysmal nocturnal haemoglobinuria

elexacaftor+tezacaftor+ivacaftor (Trikafta®)

Index

Elexacaftor+tezacaftor+ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, elexacaftor+tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

elotuzumab (Empliciti®)

Index

Elotuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, elotuzumab is subsidised for the treatment of multiple myeloma.

eltrombopag (Revolade®)

Index

Eltrombopag is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, eltrombopag is subsidised for the treatment of:

• idiopathic thrombocytopenic purpura
• severe aplastic anaemia

entrectinib (Rozlytrek®)

Index

Entrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, entrectinib is subsidised for the treatment of Stage IIIB or Stage IV non-small-cell lung cancer.

epoprostenol sodium (Flolan®/Veletri®)

Index

Epoprostenol sodium is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, epoprostenol sodium is subsidised for the treatment of pulmonary arterial hypertension.

etanercept (Enbrel®/Brenzys®)

Index

Etanercept is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, etanercept is subsidised for the treatment of:

• ankylosing spondylitis
• juvenile idiopathic arthritis
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adults
• paediatric

etrasimod (Velsipity®)

Index

Etrasimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, etrasimod is subsidised for the treatment of ulcerative colitis.

faricimab (Vabysmo®)

Index

Faricimab is a Section 85 listed pharmaceutical benefit.

Providing the patient meets specific restriction criteria, faricimab is subsidised for the treatment of:

• diabetic macular oedema
• subfoveal choroidal neovascularisation due to age related macular degeneration

golimumab (Simponi®)

Index

Golimumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, golimumab is subsidised for the treatment of:

• ankylosing spondylitis
• ulcerative colitis:
• adult
• psoriatic arthritis
• rheumatoid arthritis
• non-radiographic axial spondyloarthritis

guselkumab (Tremfya®)

Index

guselkumab is a Section 85 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, guselkumab is subsidised for the treatment of:

• Psoriatic arthritis
• Severe chronic plaque psoriasis:
• adult

iloprost trometamol (Ventavis®)

Index

Iloprost trometamol is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, iloprost trometamol is subsidised for the treatment of pulmonary arterial hypertension.

imatinib (Glivec®)

Index

Imatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, imatinib is an agent subsidised for the treatment of:

• chronic myeloid leukaemia
• gastrointestinal stromal tumour
• acute lymphoblastic leukaemia

infliximab (Remicade®/Inflectra®/ Renflexis®/Remsima®)

Index

Infliximab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, infliximab is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adults
• paediatric (Section 100 only)
• fistulising Crohn's disease
• psoriatic arthritis
• rheumatoid arthritis
• severe chronic plaque psoriasis:
• adults
• ulcerative colitis:
• adult
• paediatric (Section 100 only)

ivacaftor (Kalydeco®)

Index

Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, ivacaftor is subsidised for the treatment of cystic fibrosis.

ixekizumab (Taltz®)

Index

Ixekizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets the specific restriction criteria, ixekizumab is subsidised for the treatment of:

• ankylosing spondylitis
• psoriatic arthritis
• severe chronic plaque psoriasis:
• adult

Letter

Drugs

L-Z

See also: A-K

lanadelumab, lapatinib, larotrectinib, lenalidomide, lumacaftor+ivacaftor, macitentan, mavacamten, mecasermin, mepolizumab, midostaurin, migalastat, modafinil, nilotinib, nintedanib, nusinersen, omalizumab, onasemnogene, ozanimod, pasireotide, patisiran, pegcetacoplan, pegvisomant, pertuzumab, pirfenidone, polylactic acid, pomalidomide, ponatinib, ranibizumab, ravulizumab, riociguat, ripretinib, risankizumab, risdiplam, romiplostim, ruxolitinib, secukinumab, selinexor, selumetinib, sildenafil citrate, somatrogon, somatropin, sonidegib, sunitinib malate, tadalafil, tafamidis, teduglutide, tezacaftor+ivacaftor, tildrakizumab, tocilizumab, tofacitinib, trastuzumab emtansine, upadacitinib, ustekinumab, vedolizumab, vismodegib, vorinostat

Drugs

Description

lanadelumab (Takhzyro®)

Index

Lanadelumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, lanadelumab is subsidised for the treatment of hereditary angioedema type 1 or 2.

lapatinib (Tykerb®)

Index

Lapatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, lapatinib is subsidised for the treatment of metastatic breast cancer.

larotrectinib (Vitrakvi®)

Index

Larotrectinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, larotrectinib is subsidised for the treatment of solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive.

lenalidomide (Revlimid®)

Index

Lenalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, lenalidomide is subsidised for the treatment of:

• multiple myeloma
• myelodysplastic syndrome

lumacaftor+ivacaftor (Orkambi®)

Index

Lumacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, lumacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

macitentan (Opsumit®)

Index

Macitentan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, macitentan is subsidised for the treatment of pulmonary arterial hypertension.

mavacamten (Camzyos®)

Index

Mavacamten is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, mavacamten is subsidised for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

mecasermin (Increlex®)

Index

Mecasermin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, mecasermin is subsidised for the treatment of Severe growth failure with primary insulin-like growth factor-1 deficiency.

mepolizumab (Nucala®)

Index

Mepolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, mepolizumab is subsidised for the treatment of:

• severe asthma:
• adult
• adolescent
• chronic rhinosinusitis with nasal polyps (CRSwNP)

midostaurin (Rydapt®)

Index

Midostaurin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, midostaurin is subsidised for the treatment of acute myeloid leukaemia.

migalastat (Galafold®)

Index

Migalastat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, migalastat is subsidised for the treatment of Fabry disease.

modafinil (Modavigil®/Modafin®)

Index

Modafinil is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, modafinil is subsidised for the treatment of narcolepsy.

nilotinib (Tasigna®)

Index

Nilotinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, nilotinib is subsidised for the treatment of chronic myeloid leukaemia.

nintedanib (Ofev®)

Index

Nintedanib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, nintedanib is subsidised for the treatment of:

• idiopathic pulmonary fibrosis
• progressive fibrosing interstitial lung disease

nusinersen (Spinraza®)

Index

Nusinersen is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, nusinersen is subsidised for the treatment of spinal muscular atrophy.

omalizumab (Xolair®)

Index

Omalizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, omalizumab is subsidised for the treatment of:

• severe asthma
• chronic spontaneous urticaria

onasemnogene abeparvovec (Zolgensma®)

Index

Onasemnogene abeparvovec is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public hospital authority required.

Providing the patient meets specific restriction criteria, onasemnogene abeparvovec is subsidised for the treatment of spinal muscular atrophy.

ozanimod (Zeposia®)

Index

Ozanimod is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ozanimod is subsidised for the treatment of ulcerative colitis (adult).

pasireotide (Signifor LAR®)

Index

Pasireotide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, pasireotide is subsidised for the treatment of acromegaly.

patisiran (Onpattro®)

Index

Patisiran is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, patisiran is subsidised for the treatment of hereditary transthyretin amyloidosis.

pegcetacoplan (Empaveli®)

Index

Pegcetacoplan is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, pegcetacoplan is subsidised for the treatment of paroxysmal nocturnal haemoglobinuria.

pegvisomant (Somavert®)

Index

Pegvisomant is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority is required.

Providing the patient meets specific restriction criteria, pegvisomant is subsidised for the treatment of acromegaly.

pertuzumab (Perjeta®)

Index

Pertuzumab is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, pertuzumab is subsidised for the treatment of metastatic breast cancer.

pirfenidone (Esbriet®)

Index

Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, pirfenidone is subsidised for the treatment of idiopathic pulmonary fibrosis.

polylactic acid (Sculptra®)

Index

Pirfenidone is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, polylactic acid is subsidised for the treatment of severe facial lipoatrophy.

pomalidomide (Pomalyst®)

Index

Pomalidomide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, pomalidomide is subsidised for the treatment of multiple myeloma.

ponatinib (Iclusig®)

Index

Ponatinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ponatinib is an agent subsidised for the treatment of:

• chronic myeloid leukaemia
• acute lymphoblastic leukaemia

ranibizumab (Lucentis®)

Index

Ranibizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ranibizumab is subsidised for the treatment of:

• diabetic macular oedema
• retinal vein occlusion with macular oedema
• subfoveal choroidal neovascularisation due to:
• age related macular degeneration
• pathologic myopia
• other causes

ravulizumab (Ultomiris®)

Index

Ravulizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, ravulizumab is subsidised for the treatment of:

• paroxysmal nocturnal haemoglobinuria
• atypical haemolytic uraemic syndrome

riociguat (Adempas®)

Index

Riociguat is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, riociguat is subsidised for the treatment of:

• pulmonary arterial hypertension
• chronic thromboembolic pulmonary hypertension

ripretinib (Qinlock®)

Index

Ripretinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ripretinib is subsidised for the treatment of gastrointestinal stromal tumour.

risankizumab (Skyrizi®)

Index

Risankizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, risankizumab is subsidised for the treatment of:

• severe chronic plaque psoriasis:
• adult

risdiplam (Evrysidi®)

Index

Risdiplam is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, risdiplam is subsidised for the treatment of spinal muscular atrophy.

romiplostim (Nplate®)

Index

Romiplostim is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, romiplostim is subsidised for the treatment of idiopathic thrombocytopenic purpura.

ruxolitinib (Jakavi®)

Index

Ruxolitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, ruxolitinib is subsidised for the treatment of myelofibrosis.

secukinumab (Cosentyx®)

Index

Secukinumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, secukinumab is subsidised for the treatment of:

• ankylosing spondylitis
• hidradenitis suppurativa
• severe chronic plaque psoriasis:
• adult
• psoriatic arthritis
• non-radiographic axial spondyloarthritis

selinexor (Xpovio®)

Index

Selinexor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, selinexor is subsidised for the treatment of multiple myeloma.

selumetinib (Koselugo®)

Index

Selumetinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, selumetinib is subsidised for the treatment of neurofibromatosis type 1.

sildenafil citrate (Revatio®)

Index

Sildenafil citrate is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, sildenafil citrate is subsidised for the treatment of pulmonary arterial hypertension.

somatrogon (Ngenla®)

Index

Somatrogon is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, somatrogon is subsidised for the treatment of growth hormone deficiency (paediatric).

somatropin (Genotropin®/Norditropin®/ Nutropin®)

Index

Somatropin is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, somatropin is subsidised for the treatment of growth hormone deficiency.

sonidegib (Odomzo®)

Index

Sonidegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, sonidegib is subsidised for the treatment of basal cell carcinoma.

sunitinib malate (Sutent®)

Index

Sunitinib malate is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, sunitinib malate is subsidised for the treatment of malignant gastrointestinal stromal tumour.

tadalafil (Adcirca®)

Index

Tadalafil is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, tadalafil is used to treat patients with pulmonary arterial hypertension.

tafamidis (Vyndamax®)

Index

Tafamidis is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tafamidis is subsidised for the treatment of transthyretin amyloid cardiomyopathy.

teduglutide (Revestive®)

Index

Teduglutide is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, teduglutide is subsidised for the treatment of short bowel syndrome with intestinal failure.

tezacaftor+ivacaftor (Symdeko®)

Index

Tezacaftor+Ivacaftor is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets the specific restriction criteria, tezacaftor+ivacaftor is subsidised for the treatment of cystic fibrosis.

tildrakizumab (Ilumya®)

Index

Tildrakizumab is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tildrakizumab is subsidised for the treatment of:

• severe chronic plaque psoriasis:
• adult

tocilizumab (Actemra®)

Index

Tocilizumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through PBS Complex Drugs team.

Public and private hospital authority required (section 100 listing only).

Providing the patient meets specific restriction criteria, tocilizumab is subsidised for the treatment of:

• rheumatoid arthritis
• systemic juvenile idiopathic arthritis
• juvenile idiopathic arthritis
• giant cell arteritis

tofacitinib (Xeljanz®)

Index

Tofacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, tofacitinib is subsidised for the treatment of:

• ankylosing spondylitis
• juvenile idiopathic arthritis
• psoriatic arthritis
• rheumatoid arthritis
• ulcerative colitis:
• adult

trastuzumab emtansine (Kadcyla®/Herceptin®)

Index

Trastuzumab emtansine is listed under Section 100 - Efficient funding of chemotherapy arrangements and is administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, trastuzumab emtansine is subsidised for the treatment of:

• metastatic breast cancer
• early human epidermal growth factor receptor 2 positive breast cancer
• gastric cancer

upadacitinib (Rinvoq®)

Index

Upadacitinib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, upadacitinib is subsidised for the treatment of:

• ankylosing spondylitis
• Crohn's disease:
• adult
• non-radiographic axial spondyloarthritis
• psoriatic arthritis
• rheumatoid arthritis
• ulcerative colitis:
• adult

ustekinumab (Stelara®)

Index

Ustekinumab is a Section 85 and Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required (Section 100 only).

Providing the patient meets specific restriction criteria, ustekinumab is subsidised for the treatment of:

• severe chronic plaque psoriasis
• psoriatic arthritis
• Crohn's disease:
• adult
• fistulising Crohn's disease
• ulcerative colitis:
• adult

vedolizumab (Entyvio®)

Index

Vedolizumab is a Section 100 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Public and private hospital authority required.

Providing the patient meets specific restriction criteria, vedolizumab is subsidised for the treatment of:

• Crohn's disease:
• adult
• chronic pouchitis
• ulcerative colitis:
• adult

vismodegib (Erivedge®)

Index

Vismodegib is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, vismodegib is subsidised for the treatment of basal cell carcinoma.

vorinostat (Zolinza®)

Index

Vorinostat is a Section 85 listed pharmaceutical benefit administered through the PBS Complex Drugs team.

Providing the patient meets specific restriction criteria, vorinostat is subsidised for the treatment of cutaneous T-cell lymphoma.